Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. (Q43591852)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

A Martín

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M C Fernández-Jiménez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M D Caballero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M A Canales

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

J A Pérez-Simón

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

J García de Bustos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

L Vázquez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

F Hernández-Navarro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 April 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

161-171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11328296%20AND%20SRC:MED&resulttype=core&format=json

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphom

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X

Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02714.X